Compare Repligen Corporation Common Stock (RGEN) vs Welltower Inc. Common Stock (WELL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Welltower Inc. Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Welltower Inc. Common Stock trades at $234.4 (market cap $165.83B). The key difference: Welltower Inc. Common Stock is far larger — about 14.9× Repligen Corporation Common Stock's market cap, and Welltower Inc. Common Stock pays a 1.48% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Welltower Inc. Common Stock for 6 Days on average.
| RGEN | WELL | |
|---|---|---|
Market Cap | $11.14B | $165.83B |
Volume | 1,259,263 | 2,216,134 |
Sector | Health | Real Estate |
52-Week High | $194.57 | $252.07 |
52-Week Low | $102.87 | $172.08 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.02B | $183.59B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
WELL trades at $230.14, down 0.07% on the day, with a bullish technical signal supported by moving averages and a strong ADX trend indicator. The stock shows mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating in Q1 2026. Revenue grew to $10.67B in 2025, with net income of $936.85M, and is projected to rise to $12.6B in 2026. Analyst sentiment is strongly positive, with 71.43% buy ratings and a consensus price target of $257.08, indicating potential upside. Recent news highlights strategic acquisitions and positive coverage on senior housing demand trends.
Outlook: WELL benefits from strong demographic tailwinds in senior housing and robust analyst support, but high valuation multiples and earnings volatility pose risks. The stock's current price near support at $226 suggests a cautious entry point, with upside driven by execution on growth projections and sector tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Welltower Inc. Common Stock
Welltower is a real estate investment trust focused on healthcare properties. Its portfolio includes senior housing, outpatient medical facilities, and other health-related real estate.
Read more on WELL →
